Yale S. Michaels

Yale S. Michaels

Auto-generated profile, based on publicly available information

Yale S. Michaels

Department of Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
YMYale S. Michaels
Yale S. Michaels
MBMike B. Barnkob
Mike B. Barnkob
HBHector Barbosa
Hector Barbosa
TBToni A. Baeumler
Toni A. Baeumler
MTMary K. Thompson
Mary K. Thompson
TFTudor A. Fulga
Tudor A. Fulga
Precise, analogue regulation of gene expression is critical for cellular function in mammals. In contrast, widely employed experimental and therapeutic approaches such as knock-in/out strategies are more suitable for binary control of gene activity. Here we report on a method for precise control of gene expression levels in mammalian cells using engineered microRNA response elements (MREs). First, we measure the efficacy of thousands of synthetic MRE variants under the control of an endogenous microRNA by high-throughput sequencing. Guided by this data, we establish a library of microRNA silencing-mediated fine-tuners (miSFITs) of varying strength that can be employed to precisely control the expression of user-specified genes. We apply this technology to tune the T-cell co-inhibitory receptor PD-1 and to explore how antigen expression influences T-cell activation and tumour growth. Finally, we employ CRISPR/Cas9 mediated homology directed repair to introduce miSFITs into the BRCA1 3′UTR, demonstrating that this versatile tool can be used to tune endogenous genes.

2 April 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
DKDavid J. H. F. Knapp
David J. H. F. Knapp
YMYale S. Michaels
Yale S. Michaels
MJMax Jamilly
Max Jamilly
QFQuentin R. V. Ferry
Quentin R. V. Ferry
HBHector Barbosa
Hector Barbosa
TFTudor A. Fulga
Tudor A. Fulga
Spatial/temporal control of Cas9 guide RNA expression could considerably expand the utility of CRISPR-based technologies. Current approaches based on tRNA processing offer a promising strategy but suffer from high background. Here, to address this limitation, we present a screening platform which allows simultaneous measurements of the promoter strength, 5′, and 3′ processing efficiencies across a library of tRNA variants. This analysis reveals that the sequence determinants underlying these activities, while overlapping, are dissociable. Rational design based on the ensuing principles allowed us to engineer an improved tRNA scaffold that enables highly specific guide RNA production from a Pol-II promoter. When benchmarked against other reported systems this tRNA scaffold is superior to most alternatives, and is equivalent in function to an optimized version of the Csy4-based guide RNA release system. The results and methods described in this manuscript enable avenues of research both in genome engineering and basic tRNA biology.

26 August 2022 in Science Advances
Verified
Journal Article
Open access
YMYale S. Michaels
Yale S. Michaels
JEJohn M. Edgar
John M. Edgar
MMMatthew C. Major
Matthew C. Major
ECElizabeth L. Castle
Elizabeth L. Castle
CZCarla Zimmerman
Carla Zimmerman
PZPeter W. Zandstra
Peter W. Zandstra
T cells show tremendous efficacy as cellular therapeutics. However, obtaining primary T cells from human donors is expensive and variable. Pluripotent stem cells (PSCs) have the potential to provide a renewable source of T cells, but differentiating PSCs into hematopoietic progenitors with T cell potential remains an important challenge. Here, we report an efficient serum- and feeder-free system for differentiating human PSCs into hematopoietic progenitors and T cells. This fully defined approach allowed us to study the impact of individual proteins on blood emergence and differentiation. Providing DLL4 and VCAM1 during the endothelial-to-hematopoietic transition enhanced downstream progenitor T cell output by ~80-fold. These two proteins synergized to activate notch signaling in nascent hematopoietic stem and progenitor cells, and VCAM1 additionally promoted an inflammatory transcriptional program. We also established optimized medium formulations that enabled efficient and chemically defined maturation of functional CD8αβ + , CD4 − , CD3 + , TCRαβ + T cells with a diverse TCR repertoire.

12 April 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
MBMike B. Barnkob
Mike B. Barnkob
YMYale S. Michaels
Yale S. Michaels
VAViolaine André
Violaine André
PMPhilip S. Macklin
Philip S. Macklin
UGUzi Gileadi
Uzi Gileadi
VCVincenzo Cerundolo
Vincenzo Cerundolo
Semaphorin-3A (SEMA3A) functions as a chemorepulsive signal during development and can affect T cells by altering their filamentous actin (F-actin) cytoskeleton. The exact extent of these effects on tumour-specific T cells are not completely understood. Here we demonstrate that Neuropilin-1 (NRP1) and Plexin-A1 and Plexin-A4 are upregulated on stimulated CD8+ T cells, allowing tumour-derived SEMA3A to inhibit T cell migration and assembly of the immunological synapse. Deletion of NRP1 in both CD4+ and CD8+ T cells enhance CD8+ T-cell infiltration into tumours and restricted tumour growth in animal models. Conversely, over-expression of SEMA3A inhibit CD8+ T-cell infiltration. We further show that SEMA3A affects CD8+ T cell F-actin, leading to inhibition of immune synapse formation and motility. Examining a clear cell renal cell carcinoma patient cohort, we find that SEMA3A expression is associated with reduced survival, and that T-cells appear trapped in SEMA3A rich regions. Our study establishes SEMA3A as an inhibitor of effector CD8+ T cell tumour infiltration, suggesting that blocking NRP1 could improve T cell function in tumours.

27 January 2022 in npj Regenerative Medicine
Verified
Journal Article
Open access
PDF file
JEJohn M. Edgar
John M. Edgar
YMYale S. Michaels
Yale S. Michaels
PZPeter W. Zandstra
Peter W. Zandstra
The generation of T-cells from stem cells in vitro could provide an alternative source of cells for immunotherapies. T-cell development from hematopoietic stem and progenitor cells (HSPCs) is tightly regulated through Notch pathway activation by Delta-like (DL) ligands 1 and 4. Other molecules, such as stem cell factor (SCF) and interleukin (IL)-7, play a supportive role in regulating the survival, differentiation, and proliferation of developing T-cells. Numerous other signaling molecules influence T-lineage development in vivo, but little work has been done to understand and optimize their use for T-cell production. Using a defined engineered thymic niche system, we undertook a multi-stage statistical learning-based optimization campaign and identified IL-3 and tumor necrosis factor α (TNFα) as a stage- and dose-specific enhancers of cell proliferation and T-lineage differentiation. We used this information to construct an efficient three-stage process for generating conventional TCRαβ+CD8+T-cells expressing a diverse TCR repertoire from blood stem cells. Our work provides new insight into T-cell development and a robust system for generating T-cells to enable clinical therapies for treating cancer and immune disorders.

3 December 2021 in Science Advances
Verified
Journal Article
Open access
IRIoanna A. Rota
Ioanna A. Rota
AHAdam E. Handel
Adam E. Handel
SMStefano Maio
Stefano Maio
FKFabian Klein
Fabian Klein
FDFatima Dhalla
Fatima Dhalla
GHGeorg A. Holländer
Georg A. Holländer
A dominant transcription factor mutation disrupting nuclear liquid phase separation causes human immunodeficiency.